

CHECKPOINT TRENDS LIMITED

Formerly known as Rubra Medicaments Limited

Reg. Office: 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

Email ID: rubraltd@gmail.com | Website: www.rubramed.com

CIN: L74110MH1991PLC326598 | Tel: +91 9167469649

September 3, 2022

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code : **531099**
Sub : **Annual Report of the Company for the FY 2021-22**

Dear Sir / Madam,

In compliance with Regulation 34(1) of the SEBI (LODR) Regulations, 2015, please find attached herewith Annual Report of the Company for the FY 2021-22.

Date of Annual General Meeting - September 30, 2022.

This is for your record and information.

Thanking you,

Yours faithfully,

For **CHECKPOINT TRENDS LIMITED**

Formerly known as Rubra Medicaments Limited



Abha Kapoor
Director (Finance) and CFO
DIN – 02799429

CHECKPOINT TRENDS LIMITED

Formerly known as Rubra Medicaments Limited

Annual Report 2021 - 22

CONTENTS

PARTICULARS	PAGE NO.
Directors' Report	1-7
Details of Conservation of Energy, Technology Absorption And Foreign Exchange Earnings And Outgo	8
Extract of Nomination and Remuneration Policy	9
Corporate Governance	10 - 20
Management Discussion and Analysis	21 - 22
Secretarial Audits' Report	23 - 26
Statutory Auditors' Report	27 - 45
Balance Sheet	46
Statement of Profit and Loss Account	47
Cash Flow Statement	48
Notes to Financial Statements	49 - 53

DIRECTORS' REPORT

To,
The Members,
Checkpoint Trends Limited
Formerly known as Rubra Medicaments Limited

Your Directors have pleasure in presenting Annual Report together with the Audited Accounts of the Company for the year ended 31st March, 2022.

1. FINANCIAL RESULTS

Your Company financial performance during the year 2021-22 is summarized below:

(Rs. In Lakhs)

Particulars	2021-2022	2020-2021
Income from Operations	201.11	48.50
Other Income	0.08	-
Less: Expenses	(203.42)	(47.69)
Profit/(Loss) Before Extraordinary Items and Tax	(2.23)	0.81
Less: Extraordinary Items	-	-
Profit/(Loss) Before Tax	(2.23)	0.81
Less: Taxation	1.42	0.25
Profit/(Loss) After Tax	(3.65)	0.56
EPS (in Rs.)	(0.07)	0.01

2. FINANCIAL SUMMARY

The Company earned income from operation of Rs. 201.11 during the FY 2021-22, as compared to the income from operation of Rs. 48.50 Lakhs earned in the previous FY 2020-21. The Company's Net loss for the Financial Year ended March 31, 2022 stood at Rs. 3.65 Lakhs as against a Net Profit of Rs. 0.56 Lakhs in the previous year.

3. CHANGE IN NAME OF THE COMPANY

Subsequent to the financial year ended 2021-2022, a Special Resolution was passed by the Members through Postal Ballot on April 6, 2022 for change of name of the company from Rubra Medicaments Limited to Checkpoint Trends Limited. The company received name change certificate from ROC on May 26, 2022.

4. CHANGE IN NATURE OF BUSINESS

Subsequent to the financial year ended 2021-2022 a Special Resolution was passed by the Members through Postal Ballot on April 6, 2022 for addition to the main object of the company. The company received alteration of object clause certificate from ROC on April 25, 2022.

5. TRANSFER TO RESERVES

Profit (Loss) during the year has been transferred to Reserves.

6. CHANGES IN SHARE CAPITAL

The Authorised Share Capital of the Company is Rs. 8,20,00,000/- divided into 82,00,000 equity shares of Rs. 10/- each and the paid-up share capital of the Company is Rs. 5,46,83,000/- divided into 54,68,300 equity shares of Rs. 10/- each.

The Company has not issued any kind of shares or securities during the year under review.

7. DIVIDEND

The Board of Directors expressed their inability to recommend any dividend on equity shares for the year ended March 31, 2022.

8. PUBLIC DEPOSITS

During the year, the Company has not accepted any deposits from public nor during the previous financial year.

9. BUY-BACK / SWEAT EQUITY / BONUS SHARES

The Company has neither bought back its shares nor has issued any sweat equity or Bonus shares during the year under review.

10. EMPLOYEES STOCK OPTION PLAN

The Company has not provided any Stock Option Scheme to the Employees.

11. STATUTORY AUDITORS

The Members had appointed M/s. DD & Company (erstwhile M/s. Dinesh H. Agarwal & Company), Chartered Accountants, as Statutory Auditor of the Company at the Annual General Meeting held on September 29, 2018 for a period of three years from FY 2018-19 till FY 2020-21.

Further, M/s. DD & Company (erstwhile M/s. Dinesh H. Agarwal & Company), Chartered Accountants has been reappointed as the Statutory Auditors of the Company in the 30th Annual General Meeting held on September 30, 2021 to hold office for a further period of two (2) financial years (from FY 2021-2022 till FY 2022-2023), at a remuneration to be determined by the Board of Directors and Auditors.

12. INTERNAL AUDITOR

The Internal Auditor was appointed for a period of three years from FY 2021-22 to FY 2023-24. Hence Ms. Ankita Agawane is the Internal Auditor of the Company for the FY 2021-22.

13. STATUTORY AUDIT REPORT

The Auditors' Report on the financial statement for the current year is self-explanatory, therefore does not require any further explanation. The Company has already submitted declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 to the Stock Exchange(s).

14. COST AUDITOR REPORT AND COST RECORD

Appointment of Cost Auditor and maintenance of cost records is not applicable to the company.

15. SECRETARIAL AUDITOR AND SECRETARIAL AUDIT REPORT

Ms. Maithili Nandedkar, Practicing Company Secretary was re-appointed as Secretarial Auditor to conduct the Secretarial Audit of the Company for the Financial Years 2021-22 to 2023-24 pursuant to Section 204 of the Companies Act, 2013 and rules made there under. The Secretarial Audit Report for the Financial Year 2021-2022 forms part of the Annual Report. The Secretarial Auditors' Report to the Members for the year under review is qualified. The Secretarial Audit Report is annexed to this Report.

The secretarial Audit report for the current year is self-explanatory, therefore does not require any further explanation and listing fees has not paid due to financial crises faced by the company.

16. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB-SECTION (12) OF SECTION 143

There are no frauds reported by the Statutory Auditors of the Company under Section 143 (12).

17. DIRECTORS AND KEY MANAGERIAL PERSONNEL

In accordance with the Companies Act, none of the Directors are liable to retire by rotation at the ensuing Annual General Meeting.

During the year under review, Mr. Harish Surve was appointed as a Non-executive Independent Director of the Company for a period of 5 (Five) years, i.e., from April 15, 2021 to April 14, 2026.

Subsequent to year ended under review, subject to the approval of members in this AGM Ms. Sneha Thakur was re-appointed as an Independent Non-executive Director of the Company for a period of 5 (Five) years, i.e. from July 7, 2022 to July 6, 2027

18. ANNUAL RETURN

The Annual Return along with Notice of AGM is uploaded on the website of the Company. The web link for the same is as under: www.rubramed.com

19. DETAILS OF SUBSIDIARIES/ASSOCIATES/JOINT VENTURES, IF ANY:

As on March 31, 2022, the Company does not have any subsidiary, associate or joint venture.

20. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION & FOREIGN EXCHANGE EARNINGS AND OUTGO

The information pertaining to Conservation of Energy, Technology Absorption and Foreign Exchange earnings and outgo as required under section 134(3)(m) of the Companies Act, 2013 read with rule 8(3) of the Companies (Accounts) Rules, 2014 is annexed to this report as **Annexure I**.

21. VIGIL MEGHANISM

The Company has established a Vigil Mechanism that enables the Directors and Employees to report genuine concerns. The Vigil Mechanism provides for (a) adequate safeguards against victimization of persons who use the Vigil Mechanism; and (b) direct access to the Chairperson of the Audit Committee of the Board of Directors of the Company in appropriate or exceptional cases. The web link for the policy is as under:
<http://www.rubramed.com/policies/Whistle-Blower-Policy.pdf>

22. CORPORATE SOCIAL RESPONSIBILITY

The provisions of Corporate Social Responsibility are not applicable to the Company as it does not fall within the purview of Section 135(1) of the Companies Act, 2013.

23. RELATED PARTY TRANSACTIONS

There were no contracts or arrangements entered into by the Company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013. The related party transactions as per IND AS 24 are given in the notes to the financial accounts and forms part of the Annual Report.

The policy on Related Party Transactions is part of the website of the Company. The web link for the policy on related party transaction is as under:
<http://www.rubramed.com/policies/Related-Party-Transaction.pdf>

24. RISK MANAGEMENT

The Company has devised and implemented a mechanism for risk management.

25. FAMILIARIZATION PROGRAMME FOR INDEPENDENT DIRECTORS

The Company proactively keeps its Directors informed of the activities of the Company, its management and operations and provides an overall industry perspective as well as issues being faced by the industry. Details of the Familiarization program for Independent Directors form part of the website of the Company. The web link of Familiarization program is as under:
<http://www.rubramed.com/policies/Familiarisation-of-Independent-Director.pdf>

26. INDEPENDENT DIRECTOR'S MEETING

The Board of Directors of the Company meets once in every Financial Year without the presence of Executive Directors and Management of the Company. The role of the Directors is as per the provisions of Companies Act, 2013 as well as the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

27. DECLARATION BY INDEPENDENT DIRECTOR

Pursuant to Section 149(6) of the Companies Act, 2013 and SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, the Independent Directors of the Company have given the declaration to the Company that they qualify the criteria of independence as required under the Act.

28.A STATEMENT REGARDING OPINION OF THE BOARD WITH REGARD TO INTEGRITY, EXPERTISE AND EXPERIENCE (INCLUDING THE PROFICIENCY) OF THE INDEPENDENT DIRECTORS APPOINTED DURING THE YEAR

In the opinion of the board, the independent directors fulfill the conditions specified in SEBI (LODR) Regulations, 2015, and are independent of the management of the Company.

29. BOARD EVALUATION

Pursuant to the provisions of Companies Act, 2013 and SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, the Board has carried out annual performance evaluation of its own performance, the directors individually as well the evaluation of the working of its Audit, Nomination & Remuneration and Stakeholder committee, including the Chairman of the Board who were evaluated on parameters such as level of engagement and contribution and independence of judgment thereby safeguarding the interest of the Company. The performance evaluation of the Independent Directors was carried out by the entire Board. The performance evaluation of the Chairman and the Non Independent Directors was carried out by the Independent Directors. The Directors expressed their satisfaction with the evaluation process.

30. CORPORATE GOVERNANCE

Pursuant to Regulation 15(2) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015, compliance of Corporate Governance is not mandatory. However, the company has complied with the provisions of Regulation 17 to 27 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent possible. A separate section on Corporate Governance forms part of the Directors' Report as stipulated in Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, is included in the Annual Report as **Annexure II**.

31. STATEMENT OF COMPLIANCE OF APPLICABLE SECRETARIAL STANDARDS:

The Board hereby states that the Company has complied with all the applicable secretarial standards to the extent possible.

32. PARTICULARS OF LOANS GIVEN, GUARANTEES GIVEN OR INVESTMENTS MADE UNDER SECTION 186 OF COMPANIES ACT, 2013

Particulars of loans, guarantees and investments made by Company pursuant to Section 186 of the Companies Act, 2013 are given in the notes to the financial accounts forming part of the Annual Report. The loans and advances made by the Company, during the financial year under review, are within the limits prescribed in the section 186 of the Companies Act, 2013

33. MATERIAL CHANGES BETWEEN THE DATE OF THE BOARD REPORT AND END OF FINANCIAL YEAR

There have been no material changes and commitments affecting the financial position of the Company occurred between the end of the financial year of the Company to which the financial statements relate and the date of the report. Due to Current Pandemic situation Company's operation has come to standstill. As per MCA Circular, Current year AGM is being held through Video Conferencing. Necessary procedure is given in the AGM Notice. Members are requested to update their Email ID either by writing to the Company or through the Register or Transfer Agents.

34. SIGNIFICANT AND / OR MATERIAL ORDERS PASSED BY THE REGULATORS

No significant and/or material order was passed by any Regulator, any Court in India or any Tribunal, impacting the going concern status and the Company's operations in future.

35. THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE YEAR ALONGWITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR

As on March 31, 2022, there is no proceeding pending under the Insolvency and Bankruptcy Code, 2016.

36. THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF

There is no one time settlement done with bank or any financial institution.

37. IN CASE THE SECURITIES ARE SUSPENDED FROM TRADING, THE DIRECTORS REPORT SHALL EXPLAIN THE REASON THEREOF

The trading of the company has not been suspended.

38. NOMINATION AND REMUNERATION POLICY

An extract of the Company's policy relating to directors appointment, payment of remuneration and discharge of their duties is annexed herewith. The web link to the Nomination and Remuneration Policy is as under:

<http://www.rubramed.com/policies/NominationandRemunerationPolicy.pdf>

39. PARTICULARS OF EMPLOYEES

The Company does not have any employee/Director who is in receipt of remuneration aggregating to the sum prescribed in Section 197 of the Companies Act, 2013 ("the Act") read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

40. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The company has in place a policy for prevention of sexual harassment in accordance with the requirements of the Sexual Harassment of women at workplace (Prevention, Prohibition & Redressal) Act, 2013. Internal Complaints Committee has been set up to redress complaints received regarding sexual harassment. The Board thereafter constituted a sexual harassment committee where the chairperson of the Committee is Ms. Sneha Thakur, and Ms. Abha Kapoor and Mr. Gopal Sahu are the Members. All employees (permanent, contractual, temporary, trainees) are covered under this policy.

- a. number of complaints filed during the financial year - None
- b. number of complaints disposed of during the financial year - None
- c. number of complaints pending as on end of the financial year – None

41. TRANSFER OF AMOUNTS TO INVESTOR EDUCATION AND PROTECTION FUND

The Company does not have any funds lying unpaid or unclaimed for a period of seven years. Therefore there were no funds which were required to be transferred to Investor Education and Protection Fund (IEPF).

42. ADEQUACY OF INTERNAL FINANCIAL CONTROLS

The Company has adequate internal financial controls besides timely statutory audit and limited reviews of performance taking place periodically.

43. COVID-19 AND ITS IMPACT

During the year under review the covid-19 pandemic developed rapidly globally thereby forcing the government to enforce complete lock-down since April 2020 to June 2021 and later availability of labour as surrounding villages were not allowing residents to go for work in factories. The Board of Directors and employees maintain social distance and other precautions as per government directions. The pandemic has drastically affected the operations and the financials of the company.

44. REGISTRATION WITH INDEPENDENT DIRECTORS DATABANK

The Independent directors of the company are yet to be registered with Independent director databank.

45. DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to Section 134 of the Act, the Directors state that:

- (a) In the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures, if any;
- (b) Appropriate accounting policies have been selected and applied consistently and have made judgments and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company as at March 31, 2022 and of the profit for the Company for the year ended March 31, 2022;
- (c) Proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (d) The annual accounts have been prepared on a going concern basis;
- (e) Proper internal financial controls were followed by the Company and such internal financial controls are adequate and were operating effectively;
- (f) Proper systems are devised to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

46. ACKNOWLEDGEMENT

Your Directors takes opportunity to show gratitude towards the assistance and co-operation received from Shareholders.

For and on Behalf of the Board of Directors of
Checkpoint Trends Limited

Place: Mumbai

Date: August 11, 2022

Director

Director

ANNEXURE I

DETAILS OF CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

A. CONSERVATION OF ENERGY

(a) Major energy conservation measures taken during the year:

The Company has taken adequate measures to conserve energy by continuous monitoring and effective use of energy, which is a continuous process.

(b) Additional investment and proposals, if any, being implemented for reduction of consumption of energy:

No additional investment proposed.

(c) Impact of measures at (a) and (b) above for reduction of energy consumption and consequent impact on the cost of production of goods:

Since it is continuous process of monitoring and usage, the impact is not quantifiable.

(d) During the year company has only consumed electricity as follows:

	2021-22	2020-21
Total Electricity Expenses	NIL	NIL

B. TECHNOLOGY ABSORPTION

Particulars with respect to technology absorption are given below:

A. Research and Development (R & D)

i. Specific areas in which R & D carried out by the Company:

The Company has not carried out any research and development activities during the year under review.

ii. Benefits derived as a result of the above R & D : Not Applicable

iii. Future plan of Action : NIL

iv. Expenditure on R & D.: NIL

B. Technology absorption, adoption and innovations: NIL

C. FOREIGN EXCHANGE EARNINGS AND OUTGO: NIL

NOMINATION AND REMUNERATION POLICY

Extract of the Policy is as under:

Appointment of Directors:

The appointments of Directors are recommended by the Nomination and Remuneration Committee of the Company however all the appointments are subject to approval of Board of Directors of the Company.

Remuneration to Directors and Key Managerial Personnel:

None of the directors are entitled to any Remuneration or any sitting fees however reimbursement of expenses is allowed wherever expense is made for the Company.

Discharge of Duties:

Directors and KMP are required to perform all the duties which are mentioned under the Articles and all other duties as may be prescribed by the Board of Directors of the Company.

ANNEXURE II

CORPORATE GOVERNANCE

COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE

The Company firmly believes that Corporate Governance and compliance practices are of paramount importance in order to maintain the trust and confidence of the stakeholders, clients, and the good reputation of the Company and the unquestioned integrity of all personnel involved with the Company.

Pursuant to Regulation 15(2) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015, compliance of Corporate Governance is not mandatory. However, the company has complied with the provisions of Regulation 17 to 27 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent possible.

The Company's philosophy on Corporate Governance envisages the attainment of highest levels of transparency, accountability and equity, in all facets of its operations and in all interactions with its stakeholders, including shareholders, employees, the government and lenders.

BOARD OF DIRECTORS

The Board of Directors along with its Committees provides leadership and vision to the management and supervises the functioning of the Company. In terms of the Company's Corporate Governance Policy, all statutory and other significant and material information are placed before Board to enable it to discharge its responsibilities of strategic supervision of the Company as trustees of stakeholders.

Details of Composition of Board as on March 31, 2022 are given below:-

Sr. No.	Name of the Director	Category	Date of Appointment	Directorship in Other Companies#	Membership of Committee*	Member as Chairman of Committee
1.	Ms. Abha Kapoor	Executive Director	14/06/2016	2	0	0
2.	Ms. Sneha Thakur	Non-Executive – Independent Director	07/07/2017	0	3	3
3.	Mr. Sunil Khandalwal	Executive Director	28/05/2018	0	0	0
4.	Mr. Gopal Sahu	Non-Executive – Independent Director	11/06/2019	1	3	0
5.	Mr. Harish Surve	Non-Executive – Independent Director	15/04/2021	0	3	0

@ Mr. Harish Surve (Non-Executive Independent Director) date of appointment – April 15, 2021

#Includes Private Companies but excludes Limited Liability Partnership, Foreign Companies, Section 8 Companies & Alternate Directorship

*includes Audit Committee and Stakeholders Relationship Committee only, of all companies including this company

None of the Directors of the Company are directors in any other listed Company

Note: None of the Director is a member of more than 10 committees or acting as Chairman of more than 5 committees across all companies in which he is a director.

During the financial year 2021-22, six (06) Board Meetings were held i.e. on April 15, 2021, June 29, 2021, August 13, 2021, November 11, 2021, February 11, 2022, March 4, 2022.

ATTENDANCE OF DIRECTORS FOR THE YEAR 2021-22

Name of Director	Board Meeting	Audit Committee	Nomination and Remuneration Committee	Stakeholders Relationship Committee	AGM
Harish Surve	6 of 6	4 of 5	1 of 2	4 of 5	
Ms. Abha Kapoor	6 of 6	-	-	-	
Mr. Sunil Khandalwal	1 of 6	-	-	-	
Ms. Sneha Thakur	6 of 6	5 of 5	2 of 2	4 of 5	
Mr. Gopal Sahu	6 of 6	5 of 5	2 of 2	4 of 5	

DISCLOSURE OF RELATIONSHIP BETWEEN DIRECTORS INTER-SE

None of the Directors of the Company are related to each other. None of the Directors hold any share in the Company.

NUMBER OF SHARES AND CONVERTIBLE INSTRUMENTS HELD BY NON-EXECUTIVE DIRECTORS;

None of the Directors/KMP holds any shares in the Company

CHART OF SKILLS/EXPERTISE/COMPETENCE OF THE BOARD OF DIRECTORS:

The following are the skills/competencies determined as required for the discharge of the obligations by the Board:

Major Classification	Sub Classification	Remarks
Industry Related	Specific Skills	Good knowledge about the trading business and industry and the issues specific to the Company.
	Technical Skills	Technical/professional skills and specialist knowledge about the Company, its market, process, operations, etc. (For Executive Directors).
Strategy &	Strategy	Ability to identify and critically assess strategic opportunities and threats to the business. Guiding

Policy		development of strategies to achieve the overall goals.
	Policies	Guidance for development of policies and other parameters within which the Company should operate for better control and management.
	Crisis Management	Ability to guide crisis management and provide leadership in hours of need.
Risk & Compliance	Operational	Identification of risks related to each area of operation.
	Legal	Monitor the risks and compliances and knowledge of regulatory requirements.
	Financial	Experience in accounting and finance, ability to analyze the financial statements presented, assess the viability of various financial proposals, oversea funding arrangements and budgets.

INDEPENDENT DIRECTORS

In the opinion of the board, the independent directors fulfill the conditions specified in SEBI (LODR) Regulations, 2015, and are independent of the management of the Company.

AUDIT COMMITTEE

The terms of reference of the Audit committee include the matters specified under SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 as well as in Section 177 of the Companies Act, 2013. The terms of reference of the Audit Committee, *inter alia*, include the following:

- oversight of the listed entity's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- recommendation for appointment, remuneration and terms of appointment of auditors of the listed entity;
- approval of payment to statutory auditors for any other services rendered by the statutory auditors;
- reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to:
 - a. matters required to be included in the director's responsibility statement to be included in the board's report in terms of clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013;
 - b. changes, if any, in accounting policies and practices and reasons for the same;
 - c. major accounting entries involving estimates based on the exercise of judgment by management;
 - d. significant adjustments made in the financial statements arising out of audit findings;
 - e. compliance with listing and other legal requirements relating to financial statements;
 - f. disclosure of any related party transactions;
 - g. modified opinion(s) in the draft audit report;
- reviewing, with the management, the quarterly financial statements before submission to the board for approval;
- reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of

funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency, monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the board to take up steps in this matter;

- reviewing and monitoring the auditor’s independence, performance, and effectiveness of audit process;
- approval or any subsequent modification of transactions of the listed entity with related parties;
- scrutiny of inter-corporate loans and investments;
- valuation of undertakings or assets of the listed entity, wherever it is necessary;
- evaluation of internal financial controls and risk management systems;
- reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;
- reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- discussion with internal auditors of any significant findings and follow up there on;
- reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
- discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- to look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
- to review the functioning of the whistle blower mechanism;
- approval of appointment of chief financial officer after assessing the qualifications, experience and background, etc. of the candidate;
- Carrying out any other function as is mentioned in the terms of reference of the audit committee.

The Audit Committee met Five (5) times during the year ended March 31, 2022, i.e. on June 29, 2021, August 13, 2021, November 11, 2021 and February 11, 2022 and March 4, 2022

The Composition of Audit Committee after year ended March 31, 2022 is as under:

Name of the Member	Status
Ms. Sneha Thakur	Chairperson
Mr. Gopal Sahu	Member
Mr. Harish Surve	Member

NOMINATION AND REMUNERATION COMMITTEE

a) Brief description of terms of reference

1. formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the board of directors a policy relating to, the remuneration of the directors, key managerial personnel and other employees;
2. formulation of criteria for evaluation of performance of independent directors and the board of directors;
3. devising a policy on diversity of board of directors;
4. identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the board of directors their appointment and removal.

5. Whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors.

The Nomination & Remuneration Committee met two (2) times during the year ended April 15, 2022 and June 29, 2021

Composition

The Composition of Nomination and Remuneration after year ended March 31, 2022 is as under:

Name of the Member	Status
Ms. Sneha Thakur	Chairperson
Mr. GopalSahu	Member
Mr. Harish Surve	Member

STAKEHOLDERS RELATIONSHIP COMMITTEE

- a. The Committee looks into issues relating to shareholders / investors, including complaints relating to transfer / transmission of shares, issue of duplicate share certificates, non-receipt of annual report etc. and their redressal.
- b. The Committee presently comprises of three Members:

The Composition of Nomination and Remuneration Committee is as under:

Name of the Member	Status
Ms. Sneha Thakur	Chairperson
Mr. Harish Surve	Member
Mr. GopalSahu	Member

The Composition of Nomination and Remuneration after year ended March 31, 2022 is as under:

Name of the Member	Status
Ms. Sneha Thakur	Chairperson
Mr. GopalSahu	Member
Mr. Harish Surve	Member

- c. The Board has delegated power of approving transfer of shares to RTA.
- d. The Company Secretary of the Company is the Compliance Officer.
- e. During the year under review, no complaints were received from Shareholders / Investors.

The Stakeholder Relationship Committee met Four (4) times during the year ended March 31, 2022, i.e. on June 29, 2021, August 13, 2021, November 11, 2021 and February 11, 2022 and March 4, 2022

GENERAL BODY MEETINGS

The details of Annual General Meetings (AGM) of the Company held in last 3 years are as under:

AGM	Date	Time	Venue
2018-19	30/09/2019	10 a.m.	Registered Office
2019-20	30/09/2020	10 a.m.	Registered Office
2020-21	30/09/2021	10 a.m.	Registered Office

Director attended the last Annual General Meeting.

Details of special resolution passed in last three Annual General Meetings:

Sr. No	Particulars	Date
1.	Shift in Registered Office of the Company and consequential alteration in Memorandum of Association	29.09.2018
2.	Reappointment Of Mr. Sunil Khandalwal (Din: 07803085) As Managing Director	30.09.2021
3.	Appointment Of Mr. Harish Surve (Din: 09138943) As An Independent Director	30.09.2021

Details of Special Resolutions passed through postal ballot during the Financial Year under review and previous financial year:

FY 2020-21: NONE
FY 2019-20: NONE
FY 2018-19: NONE

Subsequent to the financial year ended 2021-2022, Members has approved change of name of the company from Rubra Medicaments Limited to Checkpoint Trends Limited also added new object to the its main object, in the postal ballot dated April 6, 2022

MEANS OF COMMUNICATION

Your Company regularly provides relevant information to the Stock Exchange as per the requirements of the provisions of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.

- The quarterly, half-yearly and Annual financial results of the Company are published in leading newspapers in India and uploaded with BSE Limited.
- The results and official news are available on www.bseindia.com and the website of the Company www.rubramed.com
- Your Company has posted all its Official News releases on its website.
- No formal representations were made to Institutional Investors or Analysts during the year under review.

MANAGEMENT DISCUSSION & ANALYSIS REPORT

The Management Discussion and Analysis Report forms part of the Annual Report as **Annexure III.**

GENERAL SHAREHOLDER INFORMATION

Detailed information in this regard is provided in section "Shareholders Information" which forms part of this Annual Report.

a. Annual General Meeting

Day & Date: September 30, 2022

Venue: Registered Office

Time: 11:00 a.m.

Financial Calendar: 1st April, 2021 to 31st March, 2022

b. Financial year April 1, 2021 – March 31, 2022 Calendar (tentative dates of declaration of Quarterly results)

1st Quarter: Within 45 Days from end of respective quarter

2nd Quarter: Within 45 Days from end of respective quarter

3rd Quarter: Within 45 Days from end of respective quarter

4th Quarter: Within 60 Days from end of respective quarter

c. Date of Book Closure : September 24, 2022 till September 26, 2022. (Both days inclusive).

d. Dividend Payment : NIL

e. Listing of Shares : Bombay Stock Exchange Limited

P.J. Towers, Dalal Street, Mumbai – 400 001

f. Listing Fees : The Company is in process of paying the Listing Fees for the financial year 2021-22

g. Stock Code & ISIN : 531099, Demat ISIN No. in NSDL & CDSL – INE396H01019

h. Market Price Data :

Month	Price on BSE (Rs.)			
	Open	High	Low	Close
Apr 2021	2.42	2.42	1.97	2.10
May 2021	2.10	3.20	2.00	3.20
June 2021	3.20	4.06	3.19	4.06
July 2021	4.06	4.06	4.06	4.06
Aug 2021	0	0	0	0
Sept 2021	3.86	3.86	3.80	3.80
Oct 2021	3.75	3.75	2.85	2.85
Nov 2021	2.75	2.75	2.27	2.60
Dec 2021	2.65	4.26	2.60	4.05
Jan 2022	4.05	4.05	4.05	4.05
Feb 2022	4.00	4.05	3.85	3.85
Mar 2022	3.85	4.04	2.80	2.95

BSE Sensex

Month	Open	High	Low	Close
Apr-21	49,868.53	50,375.77	47,204.50	48,782.36
May-21	48,356.01	52,013.22	48,028.07	51,937.44
Jun-21	52,067.51	53,126.73	51,450.58	52,482.71
Jul-21	52,638.50	53,290.81	51,802.73	52,586.84
Aug-21	52,901.28	57,625.26	52,804.08	57,552.39
Sep-21	57,763.53	60,412.32	57,263.90	59,126.36
Oct-21	58,889.77	62,245.43	58,551.14	59,306.93
Nov-21	59,577.48	61,036.56	56,382.93	57,064.87
Dec-21	57,365.85	59,203.37	55,132.68	58,253.82
Jan-22	58,310.09	58,310.09	56,409.63	58,014.17
Feb-22	58,672.86	59,618.51	54,383.20	56,247.28
Mar-22	55,629.30	58,890.92	52,260.82	58,568.51

i. Distribution of Holding (As on March 31, 2022)

Shareholding of Nominal Value	Shareholders	%	Shares	%
Upto 5,000	1068	62.2741	2072930	3.7908
5,001 – 10,000	270	15.7434	2350230	4.2979
10,001 – 20,000	134	7.8134	2165110	3.9594
20,001 – 30,000	55	3.2070	1430540	2.6161
30,001 – 40,000	24	1.3994	851980	1.5580
40,001 – 50,000	45	2.6239	2173100	3.9740
50,001 – 1,00,000	57	3.3236	4269000	7.8068
1,00,001 and above	62	3.6152	39370110	71.9970
TOTAL	1715	100	5468300	100

j. Registrar and Transfer Agent

Bigshare Services Pvt Ltd

G-10, Left Wing, Amruta Ville, OppYashoda Hospital, Raj Bhavan Road, Somajiguda, Hyderabad, Telangana - 500082, Andhra Pradesh;

Tel.:040-23374967;**Fax:** 23370295;

Email: bsshyd1@bigshareonline.com ;**Website:** www.bigshareonline.com

k. Share Transfer System: Share Transfer in physical form are generally registered and returned within 15 days from the date of receipt in case if documents are complete in all respects.

l. Outstanding GDRs/ADRs/Warrants or any convertible instruments, conversion data likely impact on Equity: NIL

m. Dematerialization of shares and liquidity: 78.06% of the shares are held in DEMAT form. Company has DEMAT connectivity with CDSL & NSDL.

Bifurcations of shares held in physical and demat form as on 31stMarch, 2022.

Particulars	No. of Shares	%
Physical Segment	11,99,100	21.92
Demat Segment		
NSDL	18,96,601	34.68
CDSL	23,72,599	43.38
Total	54,68,300	100.00

n. Nomination

Individual Shareholders holding shares singly or jointly in physical form can nominate a person in whose name the shares shall be transferable in case of death of the registered shareholder(s). Nomination facility in respect of shares held in electronic form is also available with the depository participants as per the bye-laws and business rules applicable to NSDL and CDSL. Nomination forms can be obtained from your Company's Registrar and Share Transfer Agent.

o. Address for Communication

Registered Office* : 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai 400049

Mobile No: +91 9167469649; Email ID: rubraltd@gmail.com

p. Credit Ratings: The Company has not obtained any credit rating for its securities.

s. Other Disclosures:

- (i.) Disclosures on materially significant related party transactions:
The Company does not have any materially significant related party transactions, which may have potential conflict with the interest of the Company.
- (ii.) Cases of Non-compliances / Penalties: None
- (iii.) Vigil Mechanism / Whistle Blower: Information relating to Vigil mechanism has been provided in the Board's Report. The Company has adopted the Whistle Blower Policy with direct access to Chairman of Audit Committee. The policy is available on the website of the company.
- (iv.) Details of compliance with mandatory requirements and adoption of the non-mandatory requirements: The Company has complied with all mandatory and applicable requirements. However there has been delay in LODR Compliance
The Company has complied with all mandatory and applicable requirements
- (v.) Policy for determining material subsidiaries: The Company does not have any subsidiary. Hence, the Company does not require formulating Policy for determining material subsidiaries
- (vi.) Policy on dealing with Related Party Transactions: Policy on dealing with Related Party Transactions is disseminated on the website of the company: <http://www.rubramed.com/policies/Related-Party-Transaction.pdf>
- (vii.) Commodity Price Risk or Foreign Exchange Risk and Hedging Activities: The Company has not undertaken any Foreign Exchange or hedging activities.
- (viii.) Details of utilization of funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A): Not applicable
- (ix.) Certificate from a company secretary in practice that none of the directors on the board of the company have been debarred or disqualified from being appointed or continuing as directors: Attached separately
- (x.) Recommendations of the Committee which were not accepted by the Board of Directors: None

- (xi.) Total fees for all services paid by the listed entity and its subsidiaries, on a consolidated basis, to the statutory auditor and all entities in the network firm/network entity of which the statutory auditor is a part:
There were no payments to the Statutory Auditor or other entities in the network firm/network entity of which the statutory auditor is a part by the Company, other than the audit fee and related payments as disclosed in the financial statements.
- (xii.) Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 –
- a. number of complaints filed during the financial year - NIL
 - b. number of complaints disposed of during the financial year - NIL
 - c. number of complaints pending as on end of the financial year - NIL
- (xiii.) The Register of Contracts/ Statement of related party transactions are placed before the Board/ Audit Committee regularly.
- (xiv.) None of the shares of the Company are held by the non-executive Directors of the Company.
- (xv.) There were no pecuniary transactions of the Non-executive Directors viz-a-viz the Company.
- (xvi.) The Auditors has given an unmodified opinion on the financial statement.
- (xvii.) Internal Audit Report is placed before the Audit committee.

CODE OF CONDUCT

The Company's Board of Directors has adopted the code of conduct which governs the conduct of all Directors / Employees. All Directors and senior management personnel have affirmed compliance with respective codes for the year ended on March 31, 2022. The Declaration by Board of Directors to this effect is reproduced below.

CEO/CFO CERTIFICATION

A certificate signed by Director is attached with this report.

DECLARATION

It is hereby declared that all the Board Members and Senior Managerial Personnel have affirmed compliance of code of conduct, pursuant to Corporate Governance, for the year ended 31st March 2022.

For and on Behalf of the Board of Directors of

Checkpoint Trends Limited

Place: Mumbai

Date: August 11, 2022

Director

Director

CHIEF EXECUTIVE OFFICER (CEO) / CHIEF FINANCIAL OFFICER (CFO)
CERTIFICATION

To
The Board of Directors,
Checkpoint Trends Limited
Formerly known as Rubra Medicaments Limited

I, Chief Financial Officer of the Company, do hereby certify that:

1. I have reviewed the financial statements and the cash flow statement for the year 2021-22 and to the best of our knowledge and belief:
 - a. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
 - b. These statements present a true and fair view of the Company's affair and are in compliance with existing accounting standards, applicable laws and regulations.
2. There are, to the best of my knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or in violation of the Company's Code of Conduct.
3. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and we have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
4. We have indicated to the auditors and the Audit committee:
 - a. Significant changes in internal control over financial reporting during the year;
 - b. Significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - c. Instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

For and on Behalf of the Board of Directors of
Checkpoint Trends Limited

Sd/-
Abha Kapoor
Director (Finance) & CFO
DIN: 02799429

Date: August 11, 2022
Place: Mumbai

ANNEXURE III

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

The Company is into the business of trading. The key issues of the Management Discussion and Analysis are given hereunder:

Industry Structure and Development

The recent global economic situation has witnessed immense highs and lows including some unfortunate happenings. Timing is the most important factor while trading. This fluctuates on rapid basis. According to experts most of the time markets have overvalued or undervalued. With the help of Indian market today one need to test one's financial knowledge, analytical capabilities, thought process and mental strength.

Discussion on financial performance with respect to operational performance

As mentioned earlier in the report that the company as a strategy is currently not pursuing any manufacturing business. The Company earns the profit of 0.56 Lakhs on account of trading and consultancy business during the year under review.

Segment-wise or product-wise performance

The Company is into single reportable segment only.

Outlook

Rubra Medicaments Limited remains confident of the long term growth prospects & opportunities ahead of it in its business.

Internal control system and adequacy

The system of internal control has been established to provide reasonable assurance of safeguarding assets, maintenance of proper accounting records in compliance with applicable Laws and Regulations to ensure reliability of financial statements and reports. The Statutory Auditors and the Audit Committee review all financial statements and ensure adequacy of internal control systems.

Opportunities and Threats

The strength of a company is known from sound advices. It also depends on the Government policies of taxation. Introduction of GST may give a big boost to the market.

Risks Management

Risk evaluation and management of risk is an ongoing process in the company.

Human Resources

Since your Company is in the trading industry, the criticality of talented man-power and their retention needs no emphasis. Your company is in the process of working out a comprehensive plan to attract, motivate and retain highly skilled and technically competent man-power.

Details of Significant Changes

- Debtors Turnover : 80.47 days
- Inventory Turnover : NA
- Interest Coverage Ratio : NA
- Current Ratio : 3.15
- Debt Equity Ratio - 0.05
- Operating Profit Margin: (1.11%) negative figure
- Net Profit/Loss Margin: (1.82%) negative figure

Details of change in Return on Net Worth as compared to immediately previous financial year along with the detailed explanation thereof

- Return on networth
- FY 2019-20: 5.16%
- FY 2020-21: 0.01%
- FY 2021-22: (0.67)%

Cautionary Statement

Statements in the Management discussion and analysis describing the company's objectives, projections, estimates and expectations may be "forward looking statements" within the meaning of applicable laws and regulations. Actual results could differ materially from those expressed or implied. Important factors that could make a difference to the company's operations include economic conditions affecting demand/supply and prices, conditions in the domestic and overseas markets in which the company operates/ going to operate, changes in government regulations, tax laws and other statutes and other incidental factors.

For and on Behalf of the Board of Directors of
Checkpoint Trends Limited

Sd/-
Abha Kapoor
Director (Finance) & CFO
DIN: 02799429

Date: August 11, 2022
Place: Mumbai

SECRETARIAL AUDIT REPORT

Form No. MR-3

For the financial year ended on March 31, 2022

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
CHECKPOINT TRENDS LIMITED
Formerly known as Rubra Medicaments Limited
604, 6th floor, Meghdoot,
Gulmohar Cross Road No. 6,
JVPD Scheme, Mumbai - 400049

CIN: L74110MH1991PLC326598

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **CHECKPOINT TRENDS LIMITED** (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the company has, during the audit period covering the financial year ended on **March 31, 2022** complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2022 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the Rules made there under;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under: - (***to the extent applicable during the period under review***)
- (iii) The Depositories Act, 1996 and the Regulations and Bye-Laws framed there under;
- (iv) Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; (**not applicable to the company during the audit period**)
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011: - (**not applicable during the period under review**)
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015; (**not applicable to the company during the audit period**)

- (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 **(not applicable to the company during the audit period)**;
- (d) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999;**(not applicable to the company during the audit period) ;**
- (e) The Securities and Exchange Board of India (Issue and Listing of Non Convertible Securities) Regulations, 2021; **(not applicable to the company during the audit period)**;
- (f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
- (g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2011; **(not applicable to the company during the audit period)**;
- (h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 **(not applicable to the company during the audit period)**;
- (i) The Securities and Exchange Board of India *(Share based Employee Benefits and Sweat Equity) Regulations, 2021 (not applicable to the company during the audit period)*;

(vi) I have relied on the representations made by the Company and its officers for systems and mechanism formed by the Company for compliances under other applicable Acts, Laws and Regulations to the Company.

As per management representation in writing received by me stating that during audit period, the company has adequate and proper compliance mechanism system in place for compliance of all laws applicable to the company that are into whole-sale trading business.

I have also examined compliance with the applicable Clauses of the following:

- (i) The Company has complied with Secretarial Standards pursuant to Section 118(10) of the Companies Act, 2013 with regard to Members Meeting and Board of Directors Meetings.
- (ii) Various Regulations of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as were applicable to the Company, are complied with by the company during the period under review, however, following are our observations:

Sr. No.	Action taken by	Details of violation	Details of action taken e.g. fines, warning letter, department etc.	Observation/remarks of the Practising Company Secretary, if any
1.	Regulation 14 of SEBI (Listing Obligation and Disclosures Requirement), 2015	Delay in Payment of Listing Fees to Stock Exchange	Delay in Payment of Listing Fees to Stock Exchange	Fees paid with delay

I further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

The Name of the Company Changed from "**Rubra Medicaments Limited**" to "**Checkpoint Trends Limited**" after the closing of the Financial Year.

Adequate notice is given to all the directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

I further report that:

There are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable Laws, Rules, Regulations and guidelines.

**For MNB & Co. LLP,
Company Secretaries,**

**CS Maithili Nandedkar
Partner
FCS: 8242, C P No. 9307**

**Place: Mumbai
Date: 25th May, 2022
UDIN: F008242D000370120**

Peer Review No. 1259/2021

Note: This report is to be read with my letter of even date which is annexed as Annexure herewith and forms and integral part of this report.

ANNEXURE TO SECRETARIAL AUDIT REPORT

To,
The Members,
CHECKPOINT TRENDS LIMITED
Formerly known as Rubra Medicaments Limited
604, 6th floor, Meghdoot,
Gulmohar Cross Road No. 6,
JVPD Scheme, Mumbai - 400049

My report of even date is to be read along with this letter.

1. Maintenance of secretarial records is the responsibility of the management of the Company. My responsibility is to express an opinion on these secretarial records based on my audit.
2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. I believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, I have obtained the Management representations about the compliance of Laws, Rules and Regulations and happening of events etc.
5. The compliance of the provisions of corporate and other applicable Laws, Rules, Regulations and Standards is the responsibility of management. My examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

**For MNB & Co.LLP,
Company Secretaries,**

**CS Maithili Nandedkar
Partner
FCS: 8242, C P No. 9307**

**Place: Mumbai
Date: 25th May, 2022
UDIN: F008242D000370120**

Peer Review No. 1259/2021



INDEPENDENT AUDITORS' REPORT FOR THE FINANCIAL YEAR ENDED ON 31/03/2022

To
The Members of
M/s Rubra Medicaments Limited
Mumbai

Report on the Audit of Financial Statements Opinion

We have audited the financial statements of **RUBRA MEDICAMENTS LIMITED** ("the Company"), which comprise the balance sheet as at 31st March 2022, and the statement of Profit and Loss, and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981
TEL NO: 62215449; 66712284 Email: andherica@gmail.com
Web: www.dhagarwal.com www.ddmumbai.com



affairs of the Company as at March 31, 2022, and its financial performance, and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

The company's is having accumulated losses of Rs 48872005/- in Reserve & Surplus Account as at end of the year. The company has debited a sum of Rs 10075575/- towards event expenses which is

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981
TEL NO: 62215449; 66712284 Email: andherica@gmail.com
Web: www.dhagarwal.com www.ddmumbai.com



not commensurate with the size of business and revenues reported in the financial statements. The company is has shown loss in the Profit & Loss Account. As per the management the company is still a going concern entity because it is in process of identifying new plans to improve performance of the company.

Instead of the above factors there is no uncertainty on the company's ability to continue as a going concern. The company has prepared its financial statements on a going concern basis.

Information other than the Financial Statements and Auditors' Report thereon

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report, but does not include the financial statements and our auditors' report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981

TEL NO: 62215449; 66712284 Email: andherica@gmail.com

Web: www.dhagarwal.com www.ddmumbai.com



the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981

TEL NO: 62215449; 66712284 Email: andherica@gmail.com

Web: www.dhagarwal.com www.ddmumbai.com



operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981
TEL NO: 62215449; 66712284 Email: andherica@gmail.com
Web: www.dhagarwal.com www.ddmumbai.com



always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- Evaluate the appropriateness of accounting policies used and

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981
TEL NO: 62215449; 66712284 Email: andherica@gmail.com
Web: www.dhagarwal.com www.ddmumbai.com



the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981

TEL NO: 62215449; 66712284 Email: andherica@gmail.com

Web: www.dhagarwal.com www.ddmumbai.com



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by Section 143(3) of the Act, we report that:

(1) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

(2) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

(3) The Balance Sheet, the Statement of Profit and Loss, and the

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981
TEL NO: 62215449; 66712284 Email: andherica@gmail.com
Web: www.dhagarwal.com www.ddmumbai.com



Cash Flow Statement dealt with by this Report are in agreement with the books of account.

(4) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

(5) On the basis of the written representations received from the directors as on 31st March, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2022 from being appointed as a director in terms of Section 164(2) of the Act.

(6) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, the company is exempt from getting an audit opinion on internal financial control.

(7) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

(a) The Company has disclosed details regarding pending litigations in note 28 of financial statements, which would impact its financial position.

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981

TEL NO: 62215449; 66712284 Email: andherica@gmail.com

Web: www.dhagarwal.com www.ddmumbai.com



(b) The Company does not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

(c) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

(d) (i) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(ii) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or



on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

(iii) Based on audit procedures which we considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.

(e) The company has not declared or paid any dividend during the year in contravention of the provisions of section 123 of the Companies Act, 2013.

(8) With respect to the matter to be included in the Auditors' Report under Section 197(16) of the Act, in our opinion and according to the information and explanations given to us, the limit prescribed by section 197 for maximum permissible managerial remuneration is not applicable to a private limited company.

Place: Mumbai
Date: May 25, 2022

For M/s DD & Company
Chartered Accountants
Firm Registration No: FRN 129273W



Membership No: 045393
UDIN: 22045393AJNZPC5194

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981
TEL NO: 62215449; 66712284 Email: andherica@gmail.com
Web: www.dhagarwal.com www.ddmumbai.com

**ANNEXURE OF REPORT ON CARO, 2022 FORMING
INTEGRAL PART OF THE INDEPENDENT AUDITORS'
REPORT FOR THE FINANCIAL YEAR ENDED ON 31/03/2022**

Report as required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013 (Refer to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date) With reference to the Annexure A referred to in the Independent Auditors' Report to the members of the Company on the financial statements for the year ended March 31, 2022, we report the following:

(i)(a) (A) The Company has proper records related to full particulars including quantitative details and situation of Property, Plant and Equipment. (B) the company is not having any intangible asset. Therefore, the provisions of Clause (i)(a)(B) of paragraph 3 of the order are not applicable to the company.

(b) In our opinion Property, Plant and Equipment have been physically verified by the management at reasonable intervals. No material discrepancies were noticed on such verification during the year.

(c) According to the information and explanations given to us and the records made available to us, we state that the title deeds of properties are held in the name of the Company.

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981
TEL NO: 62215449; 66712284 Email: andherica@gmail.com
Web: www.dhagarwal.com www.ddmumbai.com



(d) Details of immovable properties, which are not held in the name of the company, are given below: None

(e) The company has not revalued its Property, Building and Furniture during the year. Therefore, the provisions of Clause (i) (d) of paragraph 3 of the order are not applicable to the company.

(f) No proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder. Therefore, the provisions of Clause (i)(e) of paragraph 3 of the order are not applicable to the company.

(ii) (a) The company had no inventories during the year, therefore, there is no question of conducting any physical verification of inventory at reasonable intervals by the management and the coverage and procedure of such verification by the management is appropriate or not.

(b) During any point of time of the year, the company has not been sanctioned any working capital limits, from banks or financial institutions on the basis of security of current assets. Therefore, the provisions of Clause (ii)(b) of paragraph 3 of the order are not applicable to the company.

(iii) During the year, the company has not made any investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties. Therefore, the provisions of

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981

TEL NO: 62215449; 66712284 Email: andherica@gmail.com

Web: www.dhagarwal.com www.ddmumbai.com



clause 3(iii) of the said Order are not applicable to the company.

(iv) The company has not made any loans, investments, guarantees and security on which provisions of section 185 and 186 of the Companies Act 2013 are applicable. Therefore, the provisions of clause 3(iv) of the said Order are not applicable to the company.

(v) In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits from public. Therefore, the provisions of Clause (v) of paragraph 3 of the order are not applicable to the Company.

(vi) As explained to us, the Central Government of India has not specified the maintenance of cost records under sub-section (1) of Section 148 of the Act for any of the products of the Company. Therefore, the provisions of Clause (vi) of paragraph 3 of the order are not applicable to the Company.

(vii)(a) The Company is generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income tax, Sales Tax, Wealth tax, Service tax, Duty of Customs, duty of Excise, Value Added Tax, GST, Cess and other statutory dues with the appropriate authorities to the extent applicable to it. There are no undisputed amounts payable in respect of income tax, wealth tax, sales tax, value added tax, duty of customs, duty of excise or cess which have remained outstanding as at March 31, 2022 for a period of more than 6 months from the date they became payable.

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981
TEL NO: 62215449; 66712284 Email: andherica@gmail.com
Web: www.dhagarwal.com www.ddmumbai.com



(b) According to the information and explanations given to us, there are not any statutory dues referred in sub- clause (a) which have not been deposited on account of any dispute.

(viii) In our opinion and according to the information and explanations given to us, there is no any transaction not recorded in the books of account have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).

(ix) (a) In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of any loan or other borrowings or any interest due thereon to any lender.

(b) In our opinion and according to the information and explanations given to us, the company has not been a declared wilful defaulter by any bank or financial institution or other lender.

(c) In our opinion and according to the information and explanations given to us, the loans were applied for the purpose for which the loans were obtained.

(d) In our opinion and according to the information and explanations given to us, there are no funds raised on short term basis which have been utilized for long term purposes.

(e) In our opinion and according to the information and explanations given to us, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981

TEL NO: 62215449; 66712284 Email: andherica@gmail.com

Web: www.dhagarwal.com www.ddmumbai.com



ventures.

(f) In our opinion and according to the information and explanations given to us, the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.

(x)(a) The Company has not raised money by way of initial public offer or further public offer (including debt instruments). Therefore, the provisions of Clause (x)(a) of paragraph 3 of the order are not applicable to the Company.

(b) In our opinion and according to the information and explanations given to us, the company has not made preferential allotment or private placement of shares during the year.

(xi)(a) We have not noticed any case of fraud by the company or any fraud on the Company by its officers or employees during the year. The management has also not reported any case of fraud during the year.

(b) During the year no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.

(c) As auditor, we did not receive any whistle-blower complaint during the year.

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981
TEL NO: 62215449; 66712284 Email: andherica@gmail.com
Web: www.dhagarwal.com www.ddmumbai.com



(xii) The company is not a Nidhi Company. Therefore, the provisions of Clause (xii) of paragraph 3 of the order are not applicable to the Company.

(xiii) As per the information and explanations received to us all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act where applicable, and the details have been disclosed in the financial statements, etc., as required by the applicable accounting standards. Identification of related parties were made and provided by the management of the company.

(xiv) The company is not covered by section 138 of the Companies Act, 2013, related to appointment of internal auditor of the company. Therefore, the company is not required to appoint any internal auditor. Therefore, the provisions of Clause (xiv) of paragraph 3 of the order are not applicable to the Company.

(xv) The Company has not entered into any non-cash transactions with directors or persons connected with him for the year under review. Therefore, the provisions of Clause (xv) of paragraph 3 of the order are not applicable to the Company.

(xvi)(a) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

(b) The company has not conducted any Non-Banking Financial or Housing Finance activities during the year.

(c) The company is not a Core Investment Company (CIC) as defined in

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981

TEL NO: 62215449; 66712284 Email: andherica@gmail.com

Web: www.dhagarwal.com www.ddmumbai.com



the regulations made by the Reserve Bank of India.(d) As per the information and explanations received, the group does not have any CIC as part of the group.

(xvii) The company has incurred cash loss of Rs 365184/- in current financial year.

(xviii) There has been no resignation of the previous statutory auditors during the year.

(xix) On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, the auditor's knowledge of the Board of Directors and management plans, we are of the opinion that no material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.

(xx) There is not liability of the company under the provisions of section 135 of the Companies Act, relating to Corporate Social Responsibility. Therefore, the provisions of Clause (xx) of paragraph 3 of the order are not applicable to the Company.

(xxi) The company has not made investments in subsidiary company. Therefore, the company does not require to prepare consolidated financial statement. Therefore, the provisions of Clause (xxi) of paragraph 3 of

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981

TEL NO: 62215449; 66712284 Email: andherica@gmail.com

Web: www.dhagarwal.com www.ddmumbai.com



the order are not applicable to the Company.

Place: Mumbai
Date: May 25, 2022

For M/s DD & Company
Chartered Accountants
Firm Registration No: FRN 129273W



Proprietor
Membership No: 045393
UDIN: 22045393AJNZPC5194

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981
TEL NO: 62215449; 66712284 Email: andherica@gmail.com
Web: www.dhagarwal.com www.ddmumbai.com

Rubra Medicaments Limited
Balance Sheet as at 31st March 2022

	Particulars	Note	As at 31.03.2022	As at 31.03.2021
	1	2	(Rupees) 3	(Rupees) 4
	ASSETS			
1	Non-current asset		-	-
	Property, Plant and Equipment	5	119,928	135,896
	Total Non-Current Assets		119,928	135,896
2	Current Assets			
	Trade Receivable		6,662,500	2,205,000
	Cash and cash equivalents		14,336	86,386
	Bank balances other than (iii) above		148,887	5,076,576
	Loans	6	1,150,000	1,150,000
	Other current assets	7	373,750	392,750
	Total Current Assets		8,349,473	8,910,712
	Total Assets		8,469,401	9,046,608
1	EQUITY AND LIABILITIES			
	Equity			
	(a) Equity Share capital	2	54,683,000	54,683,000
	(b) Other Equity	3	(48,872,005)	(48,506,821)
	Total Equity		5,810,995	6,176,179
	LIABILITIES			
2	Non-current liabilities			
	Deferred tax liabilities (net)		4,134	4,134
	Total Non-Current Liabilities		4,134	4,134
3	Current liabilities			
	Trade payables		5,783	11,918
	Provisions	4	2,648,489	2,854,377
	Total Current Liabilities		2,654,272	2,866,295
	Total Liabilities		2,658,406	2,870,429
	Total equity and Liabilities		8,469,401	9,046,608
	Overview and Significant Accounting Policies	1	-	-
	The notes are an integral part of Financial Statement	12		

As per our Report of even date.

For D D & Company
Chartered Accountants



Membership No.045393

Mumbai

Date : May 25, 2022

For and on behalf of Board of Directors
Rubra Medicaments Limited

(Signature)

Director

(Signature)

Director

RUBRA MEDICAMENTS LIMITED

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH, 2022

Particulars	Note No	As At 31.03.2022 (Rupees)	As At 31.03.2021 (Rupees)
INCOME			
Revenue from operations		20,111,100	4,850,000
Other Income		8,424	227
Total		20,119,524	4,850,227
EXPENDITURE			
Purchase of Stock in Trade		5,199,270	826,273
Employee Benefit Expenses	8	2,257,000	1,954,100
Finance Cost	9	1,135	2,686
Depreciation	5	15,968	15,989
Other expenses	10	12,868,931	1,969,897
Total		20,342,304	4,768,945
Profit / (Loss) before exceptional and extraordinary items and tax		(222,780)	81,282
Exceptional Items		-	-
Profit before extraordinary items and tax		(222,780)	81,282
Extraordinary Items		-	-
Profit before tax		(222,780)	81,282
Tax expense:			
Current tax expense relating to prior years		142,404	25,000
Deferred tax		-	164
Profit(Loss) for the year after taxation		(365,184)	56,118
Earning per equity share:			
(1) Basic	11	-0.07	0.01
(2) Diluted	11	-0.07	0.01
Overview and Significant Accounting Policies	1		
The notes are an integral part of Financial Statements	12		

As per our Report of even date.

For D D & Company
Chartered Accountants



Membership No.045393
Mumbai
Date: May 25, 2022

For and on behalf of Board of Directors
Rubra Medicaments Limited

Akay...
Director

Wopul
Director

RUBRA MEDICAMENTS LIMITED

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2022

	Particulars	March 31, 2022	March 31, 2021
		RUPEES	RUPEES
A	Cash Flow From Operating Activities		
	Net Profit before tax and Extraordinary Items	(222,780)	81,282
	Adjustment for :		
	Depreciation	15,968	15,989
	Operating Profit before working Capital Changes	(206,812)	97,271
	Adjustment for Capital Changes:		
	Increase/Decrease in Current Liabilities & Provisions	(205,888)	1,447,600
	Increase/Decrease in Trade Payables	(6,135)	11,918
	Increase/Decrease in Fixed Assets	-	-
	Increase/Decrease in Cash Loans and advances	19,000	2,927,806
	Increase/Decrease in Trade Receivables	(4,457,500)	695,000
	Cash Generated From Operations	(4,857,335)	5,179,595
	Income Tax / Deferred Tax Paid	142,404	25,001
	Extraordinary items	-	-
	Net cash from Operating Activities	(4,999,739)	5,154,594
B	Net Cash From Investing Activities	-	-
C	Net Cash Flow From Financing Activities	-	-
	Net Increase (Decrease) in cash & cash equivalents (A+B+C)	(4,999,739)	5,154,594
	Opening Balance of Cash & Cash Equivalents	5,162,962	8,368
	Closing Balance of Cash & Cash Equivalents	163,223	5,162,962

As per our Report of even date.

For D D & Company

Chartered Accountants

FDL 129273W

(CA Dinesh Agastwal)

Partner

MRA/CA/ACCOUNTANTS

Membership No.045393

Mumbai

Date: May 25, 2022

For and on behalf of Board of Directors

Rubra Medicaments Limited

Akapol
Director

nopal
Director

Rubra Medicaments Limited

NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2022

PARTICULARS	AS AT 31.03.2022 (Rupees)	AS AT 31.03.2021 (Rupees)
2 SHARE CAPITAL		
Authorised 65,00,000 Equity Shares of Rs.10 each (Previous Year 65,00,000 Equity Shares of Rs.10 each)	65,00,000	65,00,000
TOTAL	65,00,000	65,00,000
Issued, Subscribed & Paid-up 54,68,300 Equity Shares of Rs.10 each (Previous Year 54,68,300 Equity Shares of Rs.10 each)	54,683,000	54,683,000
TOTAL	54,683,000	54,683,000
2.1 Reconciliation of number and amount of shares		

Particulars	As at March 31,2022		As at March 31,2021	
	Number	Amount (Rs)	Number	Amount (Rs)
Issued, Subscribed & Fully Paid up				
Equity Shares of 10/- each				
Balance as at the beginning of the year	5,468,300	54,683,000	5,468,300	54,683,000
Add : Issued during the year	-	-	-	-
Less : Buy Back of Shares	-	-	-	-
Balance as at the end of the year	5,468,300	54,683,000	5,468,300	54,683,000

2.2 Details of shares held by shareholders holding morethan 5% of the aggregate shares in the company

Particulars	As at March 31,2022		As at March 31,2021	
	No. of shares held	% of Holding	No. of shares held	% of Holding
Shriram Credit Company Limited	363,600	6.65%	363,600	6.65%
Taradevi Toshniwal	878,775	16.07%	878,775	16.07%
Religare Finvest Limited	322,000	5.89%	322,000	5.89%


2.3 Terms/Rights of Shareholders

The Company has only one class of shares referred to as equity shares having a par value of Rs.10/- per share.

Each holder of equity share is entitled to one vote per share. The Company declares and pays dividends in Indian rupees.

The dividend proposed by the Board of Directors is subject to the approval of the shareholders in ensuing Annual General Meeting.

In the event of the liquidation of the Company, the holder of equity share will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts. The distribution will be in proportion of the number of the equity shares held by the equity shareholders



RUBRA MEDICAMENTS LIMITED

NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2022

SCHEDULES TO ACCOUNTS AS AT 31st March, 2022.

Schedule 5

FIXED ASSETS

PARTICULARS	Gross Block 01.04.21	Additions	Deductions	Total	Depreciation				
					Upto 01.04.21	For The Year	Total as on 31.03.22	Net Block as on 31.03.22	Net Block as on 31.03.21
Office Equipments	66,071	-	-	66,071	12,649	6,277	18,926	47,145	53,422
Furniture & Fixture	102,000	-	-	102,000	19,526	9,691	29,217	72,783	82,474
TOTAL (Rs.)	168,071	-	-	168,071	32,175	15,968	48,143	119,928	135,896

RUBRA MEDICAMENTS LIMITED


NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021

SCHEDULES TO ACCOUNTS AS AT 31st MARCH, 2021.

Schedule 5

FIXED ASSETS

PARTICULARS	Gross Block 01.04.20	Additions	Deductions	Total	Depreciation				
					Upto 01.04.20	For The Year	Total as on 31.03.21	Net Block as on 31.03.21	Net Block as on 31.03.20
Air Sense	66,071	-	-	66,071	6,363	6,286	12,649	53,422	59,709
Furniture & Fixture	102,000	-	-	102,000	9,823	9,703	19,526	82,474	92,177
TOTAL (Rs.)	168,071	-	-	168,071	16,186	15,989	32,175	135,896	151,885



Rubra Medicaments Limited

NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2022

3 RESERVES & SURPLUS

PARTICULARS	AS AT 31.03.2022 (Rupees)	AS AT 31.03.2021 (Rupees)
State Subsidy	355,740	355,740
Share Application Money	3,375,000	3,375,000
Surplus		
Opening Balance	(52,237,561)	(52,293,679)
Add : Net profit after tax for the year	(365,184)	56,118
TOTAL	(48,872,005)	(48,506,821)

4 SHORT TERM PROVISIONS

PARTICULARS	AS AT 31.03.2022 (Rupees)	AS AT 31.03.2021 (Rupees)
Audit Fees Payable	40,000	65,000
Income Tax Payable	25,000	170,000
Salary & Wages Payable	-	1,270,000
TDS on Prof. Fees Payable	5,000	3,500
TDS on Labour Charges Payable	16,869	-
Event Expenses Payable	1,900,000	-
Duties & Taxes	661,620	1,345,877
TOTAL	2,648,489	2,854,377

6 LONG TERM LOANS & ADVANCES

PARTICULARS	AS AT 31.03.2022 (Rupees)	AS AT 31.03.2021 (Rupees)
Advnaces for Value Received	1,150,000	1,150,000
TOTAL	1,150,000	1,150,000

7 OTHER CURRENT ASSETS

PARTICULARS	AS AT 31.03.2022 (Rupees)	AS AT 31.03.2021 (Rupees)
Deposits/TDS	373,750	392,750
TOTAL	373,750	392,750



Rubra Medicaments Limited

NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2022

8 EMPLOYEE BENEFIT EXPENSES

PARTICULARS	AS AT 31.03.2022 Amount (Rs)	AS AT 31.03.2021 Amount (Rs)
Salary, Bonus & Other allownaces	2,257,000	1,954,100
TOTAL	2,257,000	1,954,100

9 FINANCE COST


PARTICULARS	AS AT 31.03.2022 Amount (Rs)	AS AT 31.03.2021 Amount (Rs)
Bank Chagres	1,135	2,686
TOTAL	1,135	2,686

10 OTHER EXPENSES

PARTICULARS	AS AT 31.03.2022 (Rupees)	AS AT 31.03.2021 (Rupees)
Advertisement Expenses	31,428	23,976
Audit Fees	50,000	50,000
Credit Card Expenses	5,000	-
Event Expenses	10,075,575	1,270,000
Legal & Professional Fees	83,800	-
Labour Charges	1,686,869	-
Listing Fee	300,000	300,000
Office Expenses	35,421	44,204
Printing & Stationery		33,670
Processing Fees	50,000	-
ROC Filing Fees	68,000	108,400
Service Charges/Custodian Fee	40,875	38,953
Share Transfer Agent	62,390	87,844
Telephone Charges	7,070	12,850
Travelling Expenses	364,703	-
Website Renewal Charges	7,800	-
TOTAL	12,868,931	1,969,897

11 EARNING PER SHARE

PARTICULARS	AS AT 31.03.2022 (Rupees)	AS AT 31.03.2021 (Rupees)
Net Profit / (Loss) after current and deferred tax	(365,184)	56,118
No. of Shares	5,468,300	5,468,300
EPS (Rs.) - Basic and Diluted	-0.07	0.01



Rubra Medicaments Limited

NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2022

12 OTHER NOTES

12.1 Segment Reporting-

The Company operates in one business segment of trading. As such, there are no separate reportable business segments as per Accounting Standard, AS-17 Segment Reporting, as prescribed by the Rules.

12.2 Related party Disclosure

As per Accounting Standard (AS18) on 'Related Party Disclosure', the related parties are as under :

During the current year, no transaction has been carried out with the related parties.

12.3 Previous year figures have been regrouped, and reclassified wherever considered necessary to conform to current year's classification

As per our Report of even date.

For D D & Company
Chartered Accountants

ERN : 129273W



(C.A. Dinesh Agarwal)
Partner

MRN : FCA/045393

Membership No.045393

Mumbai

Date: May 25, 2022

For and on behalf of Board of Directors
Rubra Medicaments Limited

Director

Director